eBook
Clinicians use various biomarkers to diagnose, track, and treat disease, and there are many disorders for which identifying new biomarkers or improving the sensitivity of existing biomarkers could fulfill unmet clinical needs and improve patient outcomes(1). For example, detecting low concentrations of neurological biomarkers in cerebrospinal fluid (CSF) and blood plays an important role in improving preclinical research, drug discovery and development, diagnostics, prognostics, monitoring, therapy, and clinical trials for various neurological disorders such as multiple sclerosis, Alzheimer’s disease, amyotrophic lateral sclerosis, traumatic brain injury, and Parkinson’s disease. Among the key neurological biomarkers are neurofilament light chain (NfL), tau phosphorylated at threonine 181 (p-Tau 181), tau phosphorylated at threonine 217 (p-Tau 217), and glial fibrillary acidic protein (GFAP). Download our ebook to read about:
- Hitting the Mark with Blood-Based Biomarkers
- Improving Neurological Biomarker Reliability
- Taking Clinical Research to the Next Level
- Next Level Blood-Based Neurological Biomarkers
(1) Dutta S, et al. Editorial: Trends in biomarkers for neurodegenerative diseases: Current research and future perspectives. Front Aging Neurosci. 2023;15:1153932.
Related Posts
NPTX2: A Synaptic Biomarker of Circuit Integrity, Cognitive Resilience, and Neurodegeneration
Neurology
Advancing Translational Neuroscience with the Simoa Mammalian GFAP Assay
Publication Brief Understanding astrocyte biology is essential for advancing translational neuroscience. GFAP has emerged as a leading biomarker of CNS injury, and Simoa® technology now enables its ultra-sensitive detection directly…
Proteomics in Transition: From Discovery to Diagnostic Relevance
Proteomics is moving beyond broad discovery to deliver real-time, clinically meaningful insights. At the forefront is Quanterix’s Simoa® digital immunoassay technology, enabling ultra-sensitive, reproducible detection of low-abundance biomarkers in areas…
Neurology
Beyond Blood: Expanding Simoa Applications in Urine, Saliva, Sweat, and Tears
Publication Brief The Quanterix Simoa® platform, known for ultrasensitive detection in plasma, serum, and CSF, now delivers the same performance in alternative matrices—urine, saliva, sweat, and tears. This publication brief…
Immunology
Simoa® IL-17A Advantage PLUS: Potential Biomarker Applications in Health and Disease
App Note IL-17A is a potent pro-inflammatory cytokine that plays critical roles in inflammatory responses, host defense against infections, and tissue regeneration. This application note delves into the physiological and…
Neurology
Beyond Blood: Tear Fluid as a Window into Biomarker Discovery
While blood and CSF have long dominated biomarker research, tear fluid is emerging as a scientifically relevant, non-invasive matrix for detecting systemic and neurological biomarkers. Produced by lacrimal glands and…
Neurology
Sweat As A Non-Invasive Matrix for Cytokine Detection Using Simoa®
Inflammatory cytokines like IL-6, IL-10, and TNF-α are central to understanding aging, immune dysregulation, and chronic disease. With eccrine glands distributed across the body, sweat offers a non-invasive, physiologically relevant…
Neurology
Expanding Access to Ultra-Sensitive Biomarker Testing: Urine as a Non-Invasive Matrix for Simoa Assays
Urine as a Non-Invasive Matrix for Ultra-Sensitive Biomarker Detection with Simoa® The Simoa® platform extends its unmatched sensitivity to urine, enabling detection of low-abundance neurological and infectious disease biomarkers in…